menu
    • menu
    [{"orgOrder":0,"company":"JGL d.d","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Undisclosed"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Undisclosed"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Poseidon Clinical Research Balkans LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Poseidon Clinical Research Balkans LLC","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Poseidon Clinical Research Balkans LLC"},{"orgOrder":0,"company":"JGL d.d","sponsor":"JGL d.d","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CROATIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nasal Irrigation With Seawater Isotonic Solution","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"JGL d.d \/ Jadran Galenski laboratorij","highestDevelopmentStatusID":"1","companyTruncated":"JGL d.d \/ Jadran Galenski laboratorij"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Poseidon CRO","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Poseidon CRO","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Poseidon CRO"}]

    Find Clinical Drug Pipeline Developments & Deals by JGL d.d

    Menu

    JGL d.d

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JGL d.d

                            Croatia arrow
                            Fall Technical Meeting
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Poseidon Clinical Research Balkans LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vizol S DIGI EYE Efficacy and Safety Study in Patients with Dry Eye

                            Details : Vizol S DIGI EYE is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Vizol S DIGI EYE

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Poseidon Clinical Research Balkans LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JGL d.d

                            Croatia arrow
                            The MedTech Conference
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Poseidon CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

                            Details : This drug candidate is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 21, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Poseidon CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            JGL d.d

                            Croatia arrow
                            Fall Technical Meeting
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            JGL d.d

                            Croatia arrow
                            The MedTech Conference
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            JGL d.d

                            Croatia arrow
                            The MedTech Conference
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nasal Irrigation With Seawater Isotonic Solution

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Undisclosed

                            Recipient : University Hospital Sestre Milosrdnice

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Nasal Isotonic Solution Irigation on Healthy Athletes' Nasal Flow and Nasal Obstruction Exercise Out...

                            Details : Nasal Irrigation With Seawater Isotonic Solution is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Nasal Obstruction.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 17, 2023

                            Lead Product(s) : Nasal Irrigation With Seawater Isotonic Solution

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Undisclosed

                            Recipient : University Hospital Sestre Milosrdnice

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth